Government Launches Mission COVID Suraksha to accelerate Indian COVID-19 Vaccine Development

▴ Government Launches Mission COVID Suraksha to accelerate Indian COVID-19 Vaccine Development
Mission COVID Suraksha is the targeted effort to enable the development of indigenous, affordable and accessible vaccines for the country and will complement the National Mission of AtmanirbharBharat

The Government of India has announced the third stimulus package of Rs. 900 Crore for the Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission. This grant will be provided to the Department of Biotechnology (DBT) for Research & Development of Indian COVID-19 vaccines.

The COVID-19 Vaccine development Mission with end-to-end focus from preclinical development through clinical development and manufacturing and regulatory facilitation for deployment would consolidate all available and funded resources towards accelerated product development. This will help accelerate the development of approx. 5-6 vaccine candidates and ensure that these are brought closer to licensure and introduction in the market for consideration of regulatory authorities for introduction in public health systems, to combat further spread of COVID infection.

The important objectives of the fund will be accelerating pre-clinical& clinical development; licensure of COVID-19 vaccine candidates that are currently in clinical stages or ready to enter the clinical stage of development, establishing clinical trial sites, and strengthening the existing immunoassay laboratories, central laboratories and suitable facilities for animal studies, production facilities and other testing facilities to support COVID-19 vaccine development. The other important objective will be supporting the development of common harmonized protocols, training, data management systems, regulatory submissions, internal and external quality management systems and accreditations. Capabilities for process development, cell line development and manufacturing of GMP batches for animal toxicology studies and clinical trials will also be supported under the Mission. A key element will be the development of suitable Target Product Profile so that vaccines being introduced through the mission have preferred characteristics applicable to India.

Led by Department of Biotechnology and implemented by a dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC), the existing activities under National Bio Pharma Mission (NBM) and Ind-CEPI Mission will provide complementary strengths to this Mission.

Phase-I of the COVID Suraksha Mission has been allotted Rs.900 Crore for a period of 12 months.

A total of 10 vaccine candidates have been supported by Department of Biotechnology so far at both academia and industry and as on date, 5 vaccine candidates are in human trials including the Russian Vaccine Sputnik-V with at least 3 more in advanced stages of preclinical to enter human trials shortly.

Dr RenuSwarup, Secretary Department of Biotechnology, Ministry of Science & Technology and Chairperson BIRAC said, “Mission COVID Suraksha is our targeted effort to enable the development of indigenous, affordable and accessible vaccines for our country and will complement the National Mission of AtmanirbharBharat”.“India has exhibited enormous strength in vaccine manufacturing and through this National COVID Vaccine Mission, we are confident that our vaccine manufacturers will develop affordable and accessible vaccine not only for India but the world”, she added.

Tags : #GovernmentofIndia #LatestCOVIDNews30thNov #FightAgainstCorona #AtmanirbharBharat #AffordableVaccine #LatestPharmaNews30thNov #DepartmentofBiotechnology #MissionCOVIDSuraksha #LatestNewsonCOVIDVaccine30thNov

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-




Trending Now

Dr. Priti Mehta, a Pediatric hematologist Oncologist explains the facts about Pre-implantation genetic diagnosisJanuary 21, 2021
The best way to lose weight is to not think about losing weight says Karishma Shah, Nutrition ConsultantJanuary 21, 2021
Demystifying Greenfield Pharma projects and Investment for the beginnersJanuary 21, 2021
Maharashtra COVID Update: Over 50,000 given COVID vaccine shots in three sessions so far January 21, 2021
1,12,007 beneficiaries vaccinated against Coronavirus, covering 11% health workersJanuary 21, 2021
Kerala continues to report surge in COVID cases with 6815 new casesJanuary 21, 2021
US studies claims vaccines are effective against the new Covid-19 strains January 21, 2021
Madhya Pradesh: Bird Flu virus found in 32 districts of state so farJanuary 20, 2021
Karnataka Health Minister expresses hope of launching Arogya Karnataka emergency health servicesJanuary 20, 2021
India starts shipments of Made in India COVID-19 Vaccines to neighbouring countriesJanuary 20, 2021
COVID-19 recovery rate improves to 98.13 pct in JharkhandJanuary 20, 2021
National COVID-19 recovery rate improves to 96.70 per centJanuary 20, 2021
Benefits of coconut waterJanuary 20, 2021
The RSA Group welcomes Eleanor Davies as Managing PartnerJanuary 19, 2021
Mask-wearing linked to reduced COVID-19 transmission, US modelling study suggestsJanuary 19, 2021
Tessa Therapeutics receives PRIME designation from EMA for CD30 CAR-T TherapyJanuary 19, 2021
FUJIFILM Diosynth Biotechnologies begins production of two COVID-19 vaccinesJanuary 19, 2021
Fried food intake linked to heightened serious heart disease and stroke riskJanuary 19, 2021
‘’What is more dangerous is that we don't have any kind of criteria to be a coach,’’ says Parag Patil, Founder, LetzRun India, and MaxFit IndiaJanuary 19, 2021
‘’The younger generation must understand that health and fitness is at least a Forty-year commitment, and not a four-month game,’’ says Shreeharsh Deshmukh, Trainer, and Nutritionist, The Fit problemJanuary 19, 2021